1. Home
  2. EMX vs RIGL Comparison

EMX vs RIGL Comparison

Compare EMX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EMX
  • RIGL
  • Stock Information
  • Founded
  • EMX N/A
  • RIGL 1996
  • Country
  • EMX Canada
  • RIGL United States
  • Employees
  • EMX N/A
  • RIGL N/A
  • Industry
  • EMX
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • EMX
  • RIGL Health Care
  • Exchange
  • EMX Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • EMX 338.0M
  • RIGL 335.5M
  • IPO Year
  • EMX N/A
  • RIGL 2000
  • Fundamental
  • Price
  • EMX $3.65
  • RIGL $38.85
  • Analyst Decision
  • EMX Strong Buy
  • RIGL Buy
  • Analyst Count
  • EMX 2
  • RIGL 5
  • Target Price
  • EMX $5.38
  • RIGL $38.20
  • AVG Volume (30 Days)
  • EMX 447.8K
  • RIGL 995.6K
  • Earning Date
  • EMX 08-11-2025
  • RIGL 08-05-2025
  • Dividend Yield
  • EMX N/A
  • RIGL N/A
  • EPS Growth
  • EMX N/A
  • RIGL N/A
  • EPS
  • EMX 0.04
  • RIGL 5.43
  • Revenue
  • EMX $29,864,000.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • EMX $11.08
  • RIGL $59.93
  • Revenue Next Year
  • EMX $3.72
  • RIGL N/A
  • P/E Ratio
  • EMX $80.97
  • RIGL $7.15
  • Revenue Growth
  • EMX N/A
  • RIGL 105.62
  • 52 Week Low
  • EMX $1.59
  • RIGL $12.66
  • 52 Week High
  • EMX $3.66
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • EMX 74.62
  • RIGL 68.57
  • Support Level
  • EMX $3.04
  • RIGL $39.00
  • Resistance Level
  • EMX $3.37
  • RIGL $42.08
  • Average True Range (ATR)
  • EMX 0.12
  • RIGL 2.32
  • MACD
  • EMX 0.03
  • RIGL -0.37
  • Stochastic Oscillator
  • EMX 97.58
  • RIGL 53.26

About EMX EMX Royalty Corporation (Canada)

EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: